25 XP   0   0   10

Marksans Pharma Limited
Buy, Hold or Sell?

Let's analyse Marksans Pharma Limited together

PenkeI guess you are interested in Marksans Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Marksans Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Marksans Pharma Limited

I send you an email if I find something interesting about Marksans Pharma Limited.

Quick analysis of Marksans Pharma Limited (30 sec.)










What can you expect buying and holding a share of Marksans Pharma Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.01
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR39.51
Expected worth in 1 year
INR88.06
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR49.45
Return On Investment
29.0%

For what price can you sell your share?

Current Price per Share
INR170.45
Expected price per share
INR122.50 - INR179.30
How sure are you?
50%

1. Valuation of Marksans Pharma Limited (5 min.)




Live pricePrice per Share (EOD)

INR170.45

Intrinsic Value Per Share

INR19.39 - INR56.37

Total Value Per Share

INR58.90 - INR95.89

2. Growth of Marksans Pharma Limited (5 min.)




Is Marksans Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$211.8m$146.7m$65m30.7%

How much money is Marksans Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$31.9m$22.1m$9.8m30.7%
Net Profit Margin14.4%12.5%--

How much money comes from the company's main activities?

3. Financial Health of Marksans Pharma Limited (5 min.)




What can you expect buying and holding a share of Marksans Pharma Limited? (5 min.)

Welcome investor! Marksans Pharma Limited's management wants to use your money to grow the business. In return you get a share of Marksans Pharma Limited.

What can you expect buying and holding a share of Marksans Pharma Limited?

First you should know what it really means to hold a share of Marksans Pharma Limited. And how you can make/lose money.

Speculation

The Price per Share of Marksans Pharma Limited is INR170.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Marksans Pharma Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Marksans Pharma Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR39.51. Based on the TTM, the Book Value Change Per Share is INR12.14 per quarter. Based on the YOY, the Book Value Change Per Share is INR7.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.23 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Marksans Pharma Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.070.0%0.070.0%0.050.0%0.050.0%0.030.0%
Usd Book Value Change Per Share0.150.1%0.150.1%0.090.1%0.070.0%0.040.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.150.1%0.150.1%0.090.1%0.070.0%0.050.0%
Usd Price Per Share0.84-0.84-0.55-0.49-0.50-
Price to Earnings Ratio11.81-11.81-10.88-10.21-34.28-
Price-to-Total Gains Ratio5.69-5.69-6.19-7.98-92.13-
Price to Book Ratio1.78-1.78-1.66-1.78-3.53-
Price-to-Total Gains Ratio5.69-5.69-6.19-7.98-92.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.0454
Number of shares488
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.150.07
Usd Total Gains Per Share0.150.07
Gains per Quarter (488 shares)72.4035.22
Gains per Year (488 shares)289.61140.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
152842806135131
21156957012269272
31685386018404413
4211137115025539554
5271421144031674695
6321706173037808836
7371990202043943977
843227423104910781118
948255826005512131259
1053284328906213471400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.04.00.076.5%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%14.03.00.082.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.00.04.076.5%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%15.02.00.088.2%

Fundamentals of Marksans Pharma Limited

About Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2024-04-01 12:09:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Marksans Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Marksans Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 14.4% means that ₹0.14 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Marksans Pharma Limited:

  • The MRQ is 14.4%. The company is making a huge profit. +2
  • The TTM is 14.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.4%TTM14.4%0.0%
TTM14.4%YOY12.5%+1.9%
TTM14.4%5Y12.6%+1.8%
5Y12.6%10Y10.2%+2.4%
1.1.2. Return on Assets

Shows how efficient Marksans Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • 12.2% Return on Assets means that Marksans Pharma Limited generated ₹0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Marksans Pharma Limited:

  • The MRQ is 12.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 12.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ12.2%TTM12.2%0.0%
TTM12.2%YOY11.3%+0.9%
TTM12.2%5Y13.3%-1.1%
5Y13.3%10Y11.4%+1.9%
1.1.3. Return on Equity

Shows how efficient Marksans Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • 15.3% Return on Equity means Marksans Pharma Limited generated ₹0.15 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Marksans Pharma Limited:

  • The MRQ is 15.3%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.3%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.3%TTM15.3%0.0%
TTM15.3%YOY15.4%-0.1%
TTM15.3%5Y18.3%-3.0%
5Y18.3%10Y19.7%-1.4%

1.2. Operating Efficiency of Marksans Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Marksans Pharma Limited is operating .

  • Measures how much profit Marksans Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 18.7% means the company generated ₹0.19  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Marksans Pharma Limited:

  • The MRQ is 18.7%. The company is operating efficient. +1
  • The TTM is 18.7%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ18.7%TTM18.7%0.0%
TTM18.7%YOY16.9%+1.8%
TTM18.7%5Y16.9%+1.9%
5Y16.9%10Y13.8%+3.0%
1.2.2. Operating Ratio

Measures how efficient Marksans Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.84 means that the operating costs are ₹0.84 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.845. The company is less efficient in keeping operating costs low.
  • The TTM is 0.845. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.845TTM0.8450.000
TTM0.845YOY0.854-0.009
TTM0.8455Y0.842+0.003
5Y0.84210Y0.866-0.024

1.3. Liquidity of Marksans Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 4.91 means the company has ₹4.91 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Marksans Pharma Limited:

  • The MRQ is 4.913. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.913. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.913TTM4.9130.000
TTM4.913YOY3.372+1.541
TTM4.9135Y3.256+1.657
5Y3.25610Y2.436+0.820
1.3.2. Quick Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 4.32 means the company can pay off ₹4.32 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Marksans Pharma Limited:

  • The MRQ is 4.325. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.325. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.325TTM4.3250.000
TTM4.325YOY2.130+2.195
TTM4.3255Y2.113+2.212
5Y2.11310Y1.536+0.577

1.4. Solvency of Marksans Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Marksans Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Marksans Pharma Limited to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.19 means that Marksans Pharma Limited assets are financed with 19.4% credit (debt) and the remaining percentage (100% - 19.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.194. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.194. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.194TTM0.1940.000
TTM0.194YOY0.254-0.060
TTM0.1945Y0.260-0.066
5Y0.26010Y0.352-0.092
1.4.2. Debt to Equity Ratio

Measures if Marksans Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 24.4% means that company has ₹0.24 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.244. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.244. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.244TTM0.2440.000
TTM0.244YOY0.347-0.103
TTM0.2445Y0.361-0.118
5Y0.36110Y0.674-0.313

2. Market Valuation of Marksans Pharma Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Marksans Pharma Limited generates.

  • Above 15 is considered overpriced but always compare Marksans Pharma Limited to the Drug Manufacturers - General industry mean.
  • A PE ratio of 11.81 means the investor is paying ₹11.81 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Marksans Pharma Limited:

  • The EOD is 28.590. Based on the earnings, the company is overpriced. -1
  • The MRQ is 11.808. Based on the earnings, the company is underpriced. +1
  • The TTM is 11.808. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD28.590MRQ11.808+16.782
MRQ11.808TTM11.8080.000
TTM11.808YOY10.879+0.929
TTM11.8085Y10.208+1.601
5Y10.20810Y34.282-24.074
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Marksans Pharma Limited:

  • The EOD is 41.429. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 17.111. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 17.111. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD41.429MRQ17.111+24.318
MRQ17.111TTM17.1110.000
TTM17.111YOY38.401-21.290
TTM17.1115Y30.945-13.834
5Y30.94510Y13.349+17.595
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Marksans Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.78 means the investor is paying ₹1.78 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Marksans Pharma Limited:

  • The EOD is 4.314. Based on the equity, the company is fair priced.
  • The MRQ is 1.782. Based on the equity, the company is underpriced. +1
  • The TTM is 1.782. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.314MRQ1.782+2.532
MRQ1.782TTM1.7820.000
TTM1.782YOY1.662+0.120
TTM1.7825Y1.776+0.005
5Y1.77610Y3.527-1.751
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Marksans Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--12.13612.1360%7.111+71%5.752+111%3.742+224%
Book Value Per Share--39.51539.5150%27.379+44%22.813+73%15.729+151%
Current Ratio--4.9134.9130%3.372+46%3.256+51%2.436+102%
Debt To Asset Ratio--0.1940.1940%0.254-24%0.260-25%0.352-45%
Debt To Equity Ratio--0.2440.2440%0.347-30%0.361-33%0.674-64%
Dividend Per Share--0.2280.2280%0.237-4%0.263-14%0.249-8%
Eps--5.9625.9620%4.182+43%3.998+49%2.686+122%
Free Cash Flow Per Share--4.1144.1140%1.185+247%2.389+72%1.380+198%
Free Cash Flow To Equity Per Share--8.5438.5430%2.965+188%3.066+179%1.554+450%
Gross Profit Margin--0.6150.6150%0.190+223%0.372+65%0.280+119%
Intrinsic Value_10Y_max--56.374--------
Intrinsic Value_10Y_min--19.388--------
Intrinsic Value_1Y_max--3.386--------
Intrinsic Value_1Y_min--1.538--------
Intrinsic Value_3Y_max--11.897--------
Intrinsic Value_3Y_min--4.998--------
Intrinsic Value_5Y_max--22.489--------
Intrinsic Value_5Y_min--8.847--------
Market Cap76138138686.400+59%31446905036.80031446905036.8000%20324349136.000+55%18287447332.480+72%18564394507.520+69%
Net Profit Margin--0.1440.1440%0.125+15%0.126+14%0.102+41%
Operating Margin--0.1870.1870%0.169+11%0.169+11%0.138+35%
Operating Ratio--0.8450.8450%0.854-1%0.842+0%0.866-2%
Pb Ratio4.314+59%1.7821.7820%1.662+7%1.776+0%3.527-49%
Pe Ratio28.590+59%11.80811.8080%10.879+9%10.208+16%34.282-66%
Price Per Share170.450+59%70.40070.4000%45.500+55%40.940+72%41.560+69%
Price To Free Cash Flow Ratio41.429+59%17.11117.1110%38.401-55%30.945-45%13.349+28%
Price To Total Gains Ratio13.786+59%5.6945.6940%6.193-8%7.983-29%92.128-94%
Quick Ratio--4.3254.3250%2.130+103%2.113+105%1.536+181%
Return On Assets--0.1220.1220%0.113+8%0.133-8%0.114+7%
Return On Equity--0.1530.1530%0.154-1%0.183-16%0.197-23%
Total Gains Per Share--12.36412.3640%7.347+68%6.015+106%3.991+210%
Usd Book Value--211808640.000211808640.0000%146756520.000+44%122285239.452+73%84309945.646+151%
Usd Book Value Change Per Share--0.1460.1460%0.085+71%0.069+111%0.045+224%
Usd Book Value Per Share--0.4740.4740%0.329+44%0.274+73%0.189+151%
Usd Dividend Per Share--0.0030.0030%0.003-4%0.003-14%0.003-8%
Usd Eps--0.0720.0720%0.050+43%0.048+49%0.032+122%
Usd Free Cash Flow--22053720.00022053720.0000%6351240.000+247%12806166.523+72%7397775.688+198%
Usd Free Cash Flow Per Share--0.0490.0490%0.014+247%0.029+72%0.017+198%
Usd Free Cash Flow To Equity Per Share--0.1030.1030%0.036+188%0.037+179%0.019+450%
Usd Market Cap913657664.237+59%377362860.442377362860.4420%243892189.632+55%219449367.990+72%222772734.090+69%
Usd Price Per Share2.045+59%0.8450.8450%0.546+55%0.491+72%0.499+69%
Usd Profit--31956960.00031956960.0000%22148280.000+44%21374514.941+50%14314552.380+123%
Usd Revenue--222256680.000222256680.0000%177614880.000+25%163615286.998+36%129806012.064+71%
Usd Total Gains Per Share--0.1480.1480%0.088+68%0.072+106%0.048+210%
 EOD+4 -4MRQTTM+0 -0YOY+29 -75Y+27 -910Y+30 -6

3.2. Fundamental Score

Let's check the fundamental score of Marksans Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1528.590
Price to Book Ratio (EOD)Between0-14.314
Net Profit Margin (MRQ)Greater than00.144
Operating Margin (MRQ)Greater than00.187
Quick Ratio (MRQ)Greater than14.325
Current Ratio (MRQ)Greater than14.913
Debt to Asset Ratio (MRQ)Less than10.194
Debt to Equity Ratio (MRQ)Less than10.244
Return on Equity (MRQ)Greater than0.150.153
Return on Assets (MRQ)Greater than0.050.122
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose178.300
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets21,903,890
Total Liabilities4,253,170
Total Stockholder Equity17,451,620
 As reported
Total Liabilities 4,253,170
Total Stockholder Equity+ 17,451,620
Total Assets = 21,903,890

Assets

Total Assets21,903,890
Total Current Assets16,753,010
Long-term Assets5,150,880
Total Current Assets
Cash And Cash Equivalents 3,824,370
Short-term Investments 3,367,200
Net Receivables 4,187,620
Inventory 4,847,390
Other Current Assets 526,430
Total Current Assets  (as reported)16,753,010
Total Current Assets  (calculated)16,753,010
+/-0
Long-term Assets
Property Plant Equipment 3,868,890
Goodwill 384,890
Intangible Assets 707,970
Other Assets 145,660
Long-term Assets  (as reported)5,150,880
Long-term Assets  (calculated)5,107,410
+/- 43,470

Liabilities & Shareholders' Equity

Total Current Liabilities3,409,900
Long-term Liabilities843,270
Total Stockholder Equity17,451,620
Total Current Liabilities
Short-term Debt 572,560
Short Long Term Debt 415,880
Accounts payable 2,306,010
Other Current Liabilities 112,380
Total Current Liabilities  (as reported)3,409,900
Total Current Liabilities  (calculated)3,406,830
+/- 3,070
Long-term Liabilities
Long term Debt Total 656,890
Other Liabilities 186,380
Long-term Liabilities  (as reported)843,270
Long-term Liabilities  (calculated)843,270
+/-0
Total Stockholder Equity
Retained Earnings 10,913,400
Accumulated Other Comprehensive Income 4,177,450
Capital Surplus 5,044,980
Total Stockholder Equity (as reported)17,451,620
Total Stockholder Equity (calculated)20,135,830
+/- 2,684,210
Other
Capital Stock453,160
Cash And Equivalents2,949,140
Cash and Short Term Investments 7,191,570
Common Stock Shares Outstanding 413,917
Current Deferred Revenue418,950
Liabilities and Stockholders Equity 21,903,890
Net Debt -2,594,920
Net Invested Capital 17,867,500
Net Tangible Assets 16,358,760
Net Working Capital 13,343,110
Property Plant and Equipment Gross 3,868,890
Short Long Term Debt Total 1,229,450



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-31
> Total Assets 
2,349,895
4,669,268
4,904,151
5,513,141
6,296,383
6,455,822
6,537,468
3,883,625
4,012,446
4,900,953
6,755,546
7,221,171
7,522,612
7,291,456
8,037,084
8,968,401
12,282,511
16,401,000
21,903,890
21,903,89016,401,00012,282,5118,968,4018,037,0847,291,4567,522,6127,221,1716,755,5464,900,9534,012,4463,883,6256,537,4686,455,8226,296,3835,513,1414,904,1514,669,2682,349,895
   > Total Current Assets 
1,333,226
3,420,560
3,572,014
2,907,634
2,606,528
2,558,659
2,132,900
2,189,263
2,439,261
3,429,451
5,088,315
4,401,454
4,837,929
4,489,515
5,314,419
5,901,874
9,022,513
12,012,000
16,753,010
16,753,01012,012,0009,022,5135,901,8745,314,4194,489,5154,837,9294,401,4545,088,3153,429,4512,439,2612,189,2632,132,9002,558,6592,606,5282,907,6343,572,0143,420,5601,333,226
       Cash And Cash Equivalents 
97,054
1,976,071
1,586,904
615,881
223,438
355,007
309,214
223,866
158,800
469,470
1,852,652
353,013
251,621
397,166
328,550
931,207
2,093,804
3,462,580
3,824,370
3,824,3703,462,5802,093,804931,207328,550397,166251,621353,0131,852,652469,470158,800223,866309,214355,007223,438615,8811,586,9041,976,07197,054
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
500
0
17,230
17,230
4,350
3,367,200
3,367,2004,35017,23017,23005000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
1,696,072
1,834,544
2,172,930
2,475,811
1,825,980
1,843,984
2,439,582
2,767,264
4,115,600
4,187,620
4,187,6204,115,6002,767,2642,439,5821,843,9841,825,9802,475,8112,172,9301,834,5441,696,072000000000
       Inventory 
524,158
789,075
1,239,349
1,394,327
1,190,799
1,045,225
672,182
733,589
776,919
1,025,887
1,301,068
1,677,917
1,900,870
2,181,241
2,932,461
2,418,439
4,043,197
4,244,420
4,847,390
4,847,3904,244,4204,043,1972,418,4392,932,4612,181,2411,900,8701,677,9171,301,0681,025,887776,919733,589672,1821,045,2251,190,7991,394,3271,239,349789,075524,158
       Other Current Assets 
712,014
655,414
745,762
897,426
1,192,291
1,158,427
1,151,505
1,231,809
1,503,543
1,934,094
1,934,595
2,370,524
2,685,438
1,911,107
209,425
112,646
118,248
185,050
526,430
526,430185,050118,248112,646209,4251,911,1072,685,4382,370,5241,934,5951,934,0941,503,5431,231,8091,151,5051,158,4271,192,291897,426745,762655,414712,014
   > Long-term Assets 
1,016,669
1,248,708
1,332,137
2,605,507
3,689,855
3,897,163
4,404,568
1,694,361
1,573,185
1,471,502
1,667,232
2,819,717
2,684,683
2,801,941
2,722,664
3,066,528
3,259,997
4,389,000
5,150,880
5,150,8804,389,0003,259,9973,066,5282,722,6642,801,9412,684,6832,819,7171,667,2321,471,5021,573,1851,694,3614,404,5683,897,1633,689,8552,605,5071,332,1371,248,7081,016,669
       Property Plant Equipment 
1,016,619
1,248,658
1,398,115
2,703,284
3,804,647
3,917,198
2,785,897
738,682
741,251
724,825
1,023,705
1,641,388
1,648,624
1,863,685
1,980,821
2,200,764
2,540,209
3,422,870
3,868,890
3,868,8903,422,8702,540,2092,200,7641,980,8211,863,6851,648,6241,641,3881,023,705724,825741,251738,6822,785,8973,917,1983,804,6472,703,2841,398,1151,248,6581,016,619
       Goodwill 
0
0
0
0
0
0
0
0
0
311,178
282,927
779,015
696,829
617,487
314,499
243,758
195,862
300,250
384,890
384,890300,250195,862243,758314,499617,487696,829779,015282,927311,178000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
8,170
0
0
0
0
0
000008,1700000000000000
       Intangible Assets 
0
0
0
0
0
0
0
914,853
0
420,493
352,344
276,142
327,898
312,603
401,943
582,640
474,357
585,690
707,970
707,970585,690474,357582,640401,943312,603327,898276,142352,344420,4930914,8530000000
       Long-term Assets Other 
50
50
19,007
10,836
4,795
102,052
1,775,777
40,827
831,934
746,676
643,527
1,159,219
1,033,381
8,166
12,920
-3,027,161
33,185
103,650
145,660
145,660103,65033,185-3,027,16112,9208,1661,033,3811,159,219643,527746,676831,93440,8271,775,777102,0524,79510,83619,0075050
> Total Liabilities 
1,326,844
3,472,941
3,640,338
4,091,973
4,786,611
4,835,735
5,387,916
5,508,192
3,077,759
3,412,773
2,876,906
2,594,321
3,014,319
2,487,316
2,510,092
2,477,157
3,228,993
4,171,290
4,253,170
4,253,1704,171,2903,228,9932,477,1572,510,0922,487,3163,014,3192,594,3212,876,9063,412,7733,077,7595,508,1925,387,9164,835,7354,786,6114,091,9733,640,3383,472,9411,326,844
   > Total Current Liabilities 
429,305
434,309
453,158
713,232
821,244
595,463
620,452
5,225,574
2,972,826
3,191,194
2,862,355
2,594,321
3,014,319
2,330,944
2,326,242
2,196,858
2,983,994
3,562,180
3,409,900
3,409,9003,562,1802,983,9942,196,8582,326,2422,330,9443,014,3192,594,3212,862,3553,191,1942,972,8265,225,574620,452595,463821,244713,232453,158434,309429,305
       Short-term Debt 
0
0
0
0
0
0
0
0
1,137,870
1,055,392
821,856
884,812
1,097,103
1,179,621
1,002,165
188,884
247,767
693,440
572,560
572,560693,440247,767188,8841,002,1651,179,6211,097,103884,812821,8561,055,3921,137,87000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
2,219,326
398,257
5,883
1,097,103
1,179,621
1,002,165
188,884
187,400
412,920
415,880
415,880412,920187,400188,8841,002,1651,179,6211,097,1035,883398,2572,219,326000000000
       Accounts payable 
0
0
0
0
0
0
0
0
560,616
831,818
1,070,195
1,189,802
1,617,841
674,806
1,060,692
1,045,010
1,686,636
2,000,790
2,306,010
2,306,0102,000,7901,686,6361,045,0101,060,692674,8061,617,8411,189,8021,070,195831,818560,61600000000
       Other Current Liabilities 
429,305
434,309
453,158
713,232
821,244
595,463
620,452
5,225,574
1,274,340
1,303,984
970,303
519,707
299,375
386,082
132,602
480,743
639,335
542,970
112,380
112,380542,970639,335480,743132,602386,082299,375519,707970,3031,303,9841,274,3405,225,574620,452595,463821,244713,232453,158434,309429,305
   > Long-term Liabilities 
897,539
3,038,632
3,187,180
3,378,741
3,965,367
4,240,272
4,767,464
282,618
104,933
221,579
14,551
0
0
156,371
183,850
280,300
244,999
609,110
843,270
843,270609,110244,999280,300183,850156,3710014,551221,579104,933282,6184,767,4644,240,2723,965,3673,378,7413,187,1803,038,632897,539
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
125,000
110,000
100,000
100,000
50,000
143,257
414,340
656,890
656,890414,340143,25750,000100,000100,000110,000125,00000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
23,425
14,551
0
50,677
70,916
83,850
122,684
101,742
194,770
186,380
186,380194,770101,742122,68483,85070,91650,677014,55123,425000000000
> Total Stockholder Equity
1,023,051
1,196,327
1,264,247
1,418,485
1,502,872
1,610,949
1,124,437
-1,680,729
864,787
1,421,824
3,797,639
4,543,245
4,445,820
4,708,646
5,424,823
6,360,143
8,864,950
12,022,700
17,451,620
17,451,62012,022,7008,864,9506,360,1435,424,8234,708,6464,445,8204,543,2453,797,6391,421,824864,787-1,680,7291,124,4371,610,9491,502,8721,418,4851,264,2471,196,3271,023,051
   Common Stock
494,406
494,406
494,406
494,406
502,806
502,806
502,807
502,807
520,307
520,307
534,314
534,314
519,314
409,314
409,314
409,314
409,314
409,310
453,160
453,160409,310409,314409,314409,314409,314519,314534,314534,314520,307520,307502,807502,807502,806502,806494,406494,406494,406494,406
   Retained Earnings 
195,284
424,198
0
0
0
0
0
0
-3,154,683
-2,539,843
-1,525,593
-920,085
-985,199
-690,702
29,784
851,091
3,349,261
5,093,090
10,913,400
10,913,4005,093,0903,349,261851,09129,784-690,702-985,199-920,085-1,525,593-2,539,843-3,154,683000000424,198195,284
   Accumulated Other Comprehensive Income 
-235,694
-313,718
-386,121
-638,466
-786,390
-936,780
-615,444
-452,915
-512,694
-563,361
-617,120
-748,070
-889,618
-1,032,203
-1,148,842
-1,331,118
3,355,050
4,788,430
4,177,450
4,177,4504,788,4303,355,050-1,331,118-1,148,842-1,032,203-889,618-748,070-617,120-563,361-512,694-452,915-615,444-936,780-786,390-638,466-386,121-313,718-235,694
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,731,870
5,044,980
5,044,9801,731,8701,751,3171,751,3171,751,3171,751,3171,751,3171,751,31700000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
569,056
591,441
1,155,962
1,562,545
1,786,456
2,044,923
1,237,074
-1,730,622
4,011,858
4,004,720
5,406,038
5,677,085
5,801,323
6,022,237
6,134,568
-4,397,771
1,751,325
1,731,870
-11,366,560
-11,366,5601,731,8701,751,325-4,397,7716,134,5686,022,2375,801,3235,677,0855,406,0384,004,7204,011,858-1,730,6221,237,0742,044,9231,786,4561,562,5451,155,962591,441569,056



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue18,521,390
Cost of Revenue-9,213,580
Gross Profit9,307,8109,307,810
 
Operating Income (+$)
Gross Profit9,307,810
Operating Expense-6,433,130
Operating Income2,877,3202,874,680
 
Operating Expense (+$)
Research Development158,890
Selling General Administrative162,620
Selling And Marketing Expenses1,025,340
Operating Expense6,433,1301,346,850
 
Net Interest Income (+$)
Interest Income91,280
Interest Expense-91,280
Other Finance Cost-91,280
Net Interest Income-91,280
 
Pretax Income (+$)
Operating Income2,877,320
Net Interest Income-91,280
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,376,5302,378,110
EBIT - interestExpense = 3,376,530
3,386,400
2,754,360
Interest Expense91,280
Earnings Before Interest and Taxes (EBIT)3,467,8103,467,810
Earnings Before Interest and Taxes (EBITDA)3,986,340
 
After tax Income (+$)
Income Before Tax3,376,530
Tax Provision-723,320
Net Income From Continuing Ops2,653,2102,653,210
Net Income2,663,080
Net Income Applicable To Common Shares2,663,080
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,646,710
Total Other Income/Expenses Net499,21091,280
 

Technical Analysis of Marksans Pharma Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Marksans Pharma Limited. The general trend of Marksans Pharma Limited is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Marksans Pharma Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Marksans Pharma Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 179.30.

The bearish price targets are: 170.85 > 130.25 > 122.50.

Tweet this
Marksans Pharma Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Marksans Pharma Limited. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Marksans Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartMarksans Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Marksans Pharma Limited. The current adx is .

Marksans Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Marksans Pharma Limited.

Marksans Pharma Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Relative Strength Index (RSI) ChartMarksans Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Marksans Pharma Limited.

Marksans Pharma Limited Daily Stochastic Oscillator ChartMarksans Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Commodity Channel Index (CCI) ChartMarksans Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartMarksans Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Marksans Pharma Limited.

Marksans Pharma Limited Daily Williams %R ChartMarksans Pharma Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Marksans Pharma Limited.

Marksans Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Average True Range (ATR) ChartMarksans Pharma Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Marksans Pharma Limited.

Marksans Pharma Limited Daily On-Balance Volume (OBV) ChartMarksans Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Money Flow Index (MFI) ChartMarksans Pharma Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Marksans Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Marksans Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose178.300
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Marksans Pharma Limited with someone you think should read this too:
  • Are you bullish or bearish on Marksans Pharma Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Marksans Pharma Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Marksans Pharma Limited

I send you an email if I find something interesting about Marksans Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Marksans Pharma Limited.

Receive notifications about Marksans Pharma Limited in your mailbox!